| Document |
Document Title |
|
WO/2017/008681A1 |
The present invention relates to an amide derivative, and the preparation method and pharmaceutical use thereof. In particular, the present invention relates to the amino derivative as represented by general formula (I), the preparation ...
|
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2017/006295A1 |
Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP...
|
|
WO/2017/006573A1 |
A side chain precursor of paclitaxel and docetaxel is provided at high purity, high yield, and low cost through a method for producing a compound shown by formula (3) using a compound shown by formula (1) as a starting compound. Using th...
|
|
WO/2016/208682A1 |
Provided are: a compound which makes it possible to produce an oxazoledicarboxylic acid compound on an industrial scale at low cost; a method for producing the compound; and a method for producing an oxazoledicarboxylic acid compound usi...
|
|
WO/2016/207785A1 |
The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active...
|
|
WO/2016/200401A1 |
The present invention relates to compounds represented by the following Formula (I). With reference to Formula (I), at least one of E1 and E2 independently is, or is independently substituted with, at least one reactive group, such as a ...
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/191872A1 |
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...
|
|
WO/2016/193470A1 |
The present invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.
|
|
WO/2016/189876A1 |
The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing t...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/188972A1 |
The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused ...
|
|
WO/2016/190616A1 |
Provided are: a compound according to an aspect, or an isomer, derivative, or pharmaceutically acceptable salt thereof; a preparation thereof; and a use thereof. Said compounds can efficiently prevent or treat degenerative brain diseases...
|
|
WO/2016/187093A1 |
Certain embodiments are directed to liposome compositions comprising a synthetic lipid composition encapsulating a scent suppressing solution.
|
|
WO/2016/082930A9 |
The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or pro...
|
|
WO/2016/177658A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful ...
|
|
WO/2016/172496A1 |
Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions ...
|
|
WO/2016/172424A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
|
|
WO/2016/168059A1 |
This disclosure relates to the field of moiecuies having pesticida i utility against pests in Phyla Arthropoda, Moliusca, and hJematoda, processes to produce such moiecuies, intermediates used In such processes, pesticidai compositions c...
|
|
WO/2016/168058A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/155831A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
|
|
WO/2016/156076A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and agrochemically acceptable salts thereof, can be used as insecticides.
|
|
WO/2016/158907A1 |
The present invention provides: a diamino-2-(benzothiazole-2-yl)diphenyl ether, which is a novel unsymmetrical diamine, and a derivative thereof; an aminonitro-2-(benzothiazole-2-yl)diphenyl ether and a dinitro-2-(benzothiazole-2-yl)diph...
|
|
WO/2016/159049A1 |
The present invention pertains to a compound that can be useful as an agent for the treatment and/or prevention of cancer, hepatitis, liver fibrosis, fatty liver, and the like.
|
|
WO/2016/153242A1 |
The present invention relates to an amide derivative compound or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a pharmaceutical composition for treating or preventing central nervous system disease, t...
|
|
WO/2016/145479A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of fibrosis and fibrosis-related conditions.
|
|
WO/2016/149464A1 |
Provided herein are compounds useful for appending amino acids to nucleophiles.
|
|
WO/2016/143652A1 |
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods. [In the fo...
|
|
WO/2016/133803A1 |
In one aspect, the invention relates to a compound of the structure: (1), or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention rel...
|
|
WO/2016/126572A2 |
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...
|
|
WO/2016/127186A1 |
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including m...
|
|
WO/2016/125622A1 |
A benzoxazole compound represented by formula (I) (in the formula: A represents nitrogen or CR5; one from among RA and RB represents -OSO2CF3, and the other represents hydrogen; R1 represents a C1-C4 alkyl group, a cyclopropyl group, or ...
|
|
WO/2016/121691A1 |
Provided is a resin which has a low linear thermal expansion coefficient and a low absorbance. This resin is characterized by comprising at least one structure that is selected from among structures represented by general formula (1) or ...
|
|
WO/2016/116445A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and agrochemically acceptable salts and enantiomers thereof, can be used as insecticides.
|
|
WO/2016/114668A1 |
The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a p...
|
|
WO/2016/109501A1 |
The present invention is directed to amide compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment or prevention of diseases or disorders associated with peripheral ...
|
|
WO/2016/108282A1 |
A compound represented by general formula (III), and the use of a tautomer or stereoisomer of said compound, or a pharmacologically acceptable salt or solvate thereof, as a treatment for gout or hyperuricemia. (III) (In the formula, R1a,...
|
|
WO/2016/105449A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...
|
|
WO/2016/105448A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in ...
|
|
WO/2016/101887A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/097626A1 |
The invention relates to novel compounds, to the synthesis method thereof and to the use of same in medicine and in cosmetics. The invention relates to novel compounds, ligands that modulate RAR receptors.
|
|
WO/2016/097389A1 |
The invention relates to benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan rece...
|
|
WO/2016/087384A1 |
The invention relates to a method for producing Heonon(meth)acrylate via the transesterification of alkyl(meth)acrylate with Heonon, comprising the following steps: (i) permitting alkyl(meth)acrylate to react with Heonon in the presence ...
|
|
WO/2016/088749A1 |
The present invention addresses the problem of providing: a polymerizable compound which has good liquid crystallinity, good orientation, enough solubility in solvents, high storage stability in a state of solution, and high optical stab...
|
|
WO/2016/088103A1 |
The present invention provides a process for the preparation of tedizolid phosphate.
|
|
WO/2016/084816A1 |
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...
|
|
WO/2016/066115A1 |
Provided is a compound as shown by formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, pharmaceutically acceptable salts, hydrates or solvates thereof, and a preparation method and a use of ...
|
|
WO/2016/065583A1 |
Oxazole compounds which are antagonists of orexin receptors, pharmaceutical compositions thereof and their uses in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are...
|
|
WO/2016/067194A1 |
The present invention provides a process for the preparation of anacetrapib and an intermediate thereof.
|
